吡柔比星膀胱灌注化疗对膀胱癌术后患者的治疗效果  

Effect of intravesical instillation of pirarubicin on patients with bladder cancer after operation

作　　者：李振国 吕建阳[1] 陈林[1] LI Zhenguo;LYU Jianyang;CHEN Lin(Department of Urological Surgery,the Sixth Hospital of Beijing,Beijing 100007,China)

机构地区：[1]北京市第六医院泌尿外科,北京100007

出　　处：《癌症进展》2018年第13期1641-1643,1667,共4页Oncology Progress

摘　　要：目的分析吡柔比星膀胱灌注化疗对膀胱癌患者的治疗效果。方法回顾性分析80例接受化疗的膀胱癌术后患者的临床资料,根据术后化疗方法不同,分为对照组40例(常规静脉化疗)和观察组40例(常规静脉化疗联合吡柔比星膀胱灌注化疗)。比较两组患者治疗前后血管内皮生长因子(VEGF)水平、成纤维细胞生长因子(FGF)水平、肿瘤标志物水平、肝肾功能、不良反应的发生率及1年复发率。结果治疗前,两组患者的VEGF、FGF、癌胚抗原(CEA)、糖类抗原19-9(CA19-9)、糖类抗原125(CA125)、丙氨酸转氨酶(ALT)、天冬氨酸转氨酶(AST)、肌酐水平比较,差异均无统计学意义(P>0.05);治疗后,观察组患者的VEGF、FGF、CEA、CA19-9、CA125、ALT、AST、肌酐水平均明显低于对照组,差异均有统计学意义(P<0.01)。两组患者不良反应的总发生率和1年复发率比较,差异均无统计学意义(P>0.05)。结论吡柔比星膀胱灌注化疗对膀胱癌术后患者有较好的治疗效果,可以降低患者的VEGF、FGF水平,且不会增加不良反应的发生率,具有良好的应用价值。Objective To observe the therapeutic effect of intravesical instillation of pirambicin on bladder cancer. The clinical data of 80 patients with bladder cancer who received chemotherapy were retrospectively analyzed, by respective postoperative chemotherapy administered, these patients were stratified as control group （with conventional intravenous chemotherapy） and study group （conventional intravenous chemotherapy combined with intravesical instillation of pirarubicin）, of which the vascular endothelial growth factor （VEGF）, fibroblast growth factor （FGF）, tumor mark- er level, liver and kidney function before and after treatment, as well as the incidence of adverse reaction and recurrence rate in 1 year after treatment were compared between the two groups. ： Before treatment, the VEGF, FGF, carcino- embryonic antigen （CEA）, carbohydrate antigen 19-9 （CA 19-9）, carbohydrate antigen 125 （CA 125）, alanine aminotrans-ferase （ALT）, aspartate aminotransferase （AST） and creatiinne levels were similar in the two groups （P〉0.05）; while after treatment, the VEGF, FGF, CEA, CA19-9, CA125, ALT, AST and creatinine levels were lower in study group compared with control group, showing statistically significant difference （P〈0.01）. The overall incidence of adverse reaction and re- currence rate in 1 year after treatment, and the differences were of no statistical significance （P〉0.05）. Intravesical instillation of pirarubicin is clinically effective in the treatment of patients with bladder cancer, by lowering the level of VEGF and FGF, with no increased incidence of adverse reactions, thus is clinically applicable.

关 键 词：吡柔比星 膀胱癌 血管内皮生长因子 肝肾功能 

分 类 号：R737.14[医药卫生—肿瘤]